Objective-High-density lipoprotein cholesterol efflux capacity (CEC) is inversely associated with incident cardiovascular events, independent of high-density lipoprotein cholesterol. Obesity is often characterized by impaired high-density lipoprotein function. However, the effects of different bariatric surgical techniques on CEC have not been compared. This study sought to determine the effects of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on CEC. Approach and Results-We prospectively studied severely obese, nondiabetic, premenopausal Hispanic women not using lipid medications undergoing RYGB (n=31) or SG (n=36). Subjects were examined before and at 6 and 12 months after surgery. There were no differences in baseline characteristics between surgical groups. Preoperative CEC correlated most strongly with Apo A1 (apolipoprotein A1) concentration but did not correlate with body mass index, waist:hip, highsensitivity C-reactive protein, or measures of insulin resistance. After 6 months, SG produced superior response in highdensity lipoprotein cholesterol and Apo A1 quantity, as well as global and non-ABCA1 (ATP-binding cassette transporter A1)-mediated CEC (P=0.048, P=0.018, respectively) versus RYGB. In multivariable regression models, only procedure type was predictive of changes in CEC (P=0.05). At 12 months after SG, CEC was equivalent to that of normal body mass index control subjects, whereas it remained impaired after RYGB. Conclusions-SG and RYGB produce similar weight loss, but contrasting effects on CEC. These findings may be relevant in discussions about the type of procedure that is most appropriate for a particular obese patient. Further study of the mechanisms underlying these changes may lead to improved understanding of the factors governing CEC and potential therapeutic interventions to maximally reduce cardiovascular disease risk in both obese and nonobese patients. Visual Overview-An online visual overview is available for this article. surgery. It may also provide insight on factors governing CEC, and in turn, potential therapeutic interventions to reduce CVD risk in both obese and nonobese patients. With this background, the present study sought to prospectively investigate the effect of the 2 most commonly performed bariatric surgical procedures, Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), on HDL function in CEC, using the common assay using J774A.1 cells and ApoB (apolipoprotein B)-depleted serum.
T
he World Health Organization estimates that nearly one quarter of the worldwide cardiovascular disease (CVD) burden is attributable to obesity. 1 Dyslipidemia, frequently present in obesity, seems to explain much of the increased risk for CVD. 2 Obesity is often characterized by low levels of highdensity lipoprotein cholesterol (HDL-C), as well as impaired HDL function. [3] [4] [5] [6] [7] [8] [9] [10] [11] HDL has antioxidative, anti-inflammatory, and antithrombotic actions, [12] [13] [14] but HDL's participation in cholesterol efflux-removal of cholesterol from the periphery and atherosclerotic plaques as the first step within the process of reverse cholesterol transport-has been considered to be the foremost mechanism for its association with reduced CVD risk. 12 Over the past several years, many prospective studies have demonstrated inverse associations between cholesterol efflux capacity (CEC) and incident cardiovascular events. 4, 5, 15, 16 The effects of weight loss on plasma HDL-C levels have been well studied. [17] [18] [19] [20] Previous work has determined that the weight loss modality-be it dietary modification, exercise, or bariatric surgery-influences the changes in HDL-C, as does the degree of weight loss. 21 Less characterized are the effects of weight loss on HDL function in CEC, which is only modestly associated with HDL-C, and has not been found to improve with nonsurgical weight loss. 10, 22, 23 The few published assessments of the effect of bariatric surgery on CEC are limited by short durations of follow-up and sample sizes. 3, 24, 25 Further, no head-to-head comparison of the effects of bariatric procedures on CEC has been performed.
To date, there has been little investigation of the effects of surgical weight loss on HDL function, and specifically on CEC-the only measure of HDL function independently associated with prospective cardiovascular events. Identifying interventions which avoid loss of HDL function and, ideally, produce sustained enhancement may aid in determining the most appropriate procedure for a particular patient pursuing bariatric surgery. It may also provide insight on factors governing CEC, and in turn, potential therapeutic interventions to reduce CVD risk in both obese and nonobese patients. With this background, the present study sought to prospectively investigate the effect of the 2 most commonly performed bariatric surgical procedures, Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), on HDL function in CEC, using the common assay using J774A.1 cells and ApoB (apolipoprotein B)-depleted serum. 26 
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Eight hundred fifty-eight patients were screened, with 109 satisfying enrollment criteria and consenting to participate in the study ( Figure I in the online-only Data Supplement). Seventyfour women presented for baseline testing and underwent surgery. One subject became pregnant before her 6 month follow-up visit, another started an exclusionary medication after surgery, and 5 did not return for 6-month visits.
Subjects were young (32.7±8.0 years) and severely obese (43.8±6.4 kg/m 2 ), and although none required medications to treat insulin resistance or dyslipidemia, half of subjects undergoing each procedure met criteria for the metabolic syndrome 27 before surgery ( In comparison to normal body mass index (BMI) subjects (n=8) recruited from the same outpatient population, obese subjects had similar concentrations of total HDL particles, but lower HDL-C and fewer large HDL particles, with a trend toward lower Apo A1 concentrations (P=0.10; Table  I in the online-only Data Supplement). Obese subjects also exhibited significantly lower global and non-ABCA1 (ATPbinding cassette transporter A1)-mediated CEC than normal BMI subjects.
Effects of Bariatric Surgery
At 6 months, both surgical procedures had reduced mean BMI, waist circumference, blood pressure, triglycerides, highsensitivity C-reactive protein, homeostatic model assessmentinsulin resistance, and hemoglobin A1c, while increasing average adiponectin and large HDL particles ( Table 2 ). Average percent change from preoperative values for several variables differed significantly between procedures, notably, concentrations of HDL-C, HDL particles, and Apo A1 ( Figure 1 ; Table  II in the online-only Data Supplement).
SG and RYGB produced contrasting effects on CEC, with RYGB reducing and SG increasing global and non-ABCA1-mediated CEC at 6 months ( Figure 2 ). Both procedures were associated with decreased cAMP-inducible (for the upregulation of ABCA1 in J774A.1 cells) CEC, with a trend toward greater reductions after RYGB. Fewer than one third of RYGB subjects (10/31) manifest improved global CEC, whereas more than half of SG subjects (20/36) exhibited improved global CEC, at 6 months (P=0.05). The proportion of subjects with increased non-ABCA1-mediated CEC (25/36 versus 13/31; P=0.03) was also greater after SG than RYGB, with cAMP-inducible CEC exhibiting a trend toward a difference between procedures (13/36 versus 6/31; P=0.13).
Predictors of CEC
Preoperative CEC was associated most strongly with plasma Apo A1 concentrations. There were also strong correlations with HDL-C, HDL particle concentration, and large HDL particles (particularly with non-ABCA1-mediated CEC; Table 3 ). Of note, correlations between CEC and these variables were stronger in our normal BMI cohort (Table III in the online-only Data Supplement). After surgery, the strengths of association between HDL parameters and CEC increased (Table 4) .
Notably, the only preoperative variable predictive of response in CEC at 6 months in multivariable regression models was surgical procedure (Tables IV through VI in postoperative changes in clinical and hematologic variables revealed that changes in Apo A1 concentration were most predictive of global and non-ABCA1-mediated CEC and that changes in HDL-C were most predictive of cAMP-inducible CEC, at 6 months after surgery (Tables 5 through 7) . These associations held regardless of procedure (data not shown).
The associations of several blood measures with CEC differed before and after bariatric surgery (Tables 8 and 9 ). Most notably, HDL-C, HDL particles, and Apo A1 ( Figure 3) were no longer associated with cAMP-inducible CEC at 6 months after RYGB, but continued to be associated with this measure after SG.
Sensitivity Analyses
To obtain more specific assessments of the effects of the procedures on CEC, we compared 6-month postoperative CEC response by procedure in 4 sensitivity analyses described in Methods. These analyses demonstrated identical findings to those of data from the entire cohort-superior changes in CEC after SG, relative to RYGB. Notably, the magnitudes of differences in postoperative changes in CEC between procedures in sensitivity analyses were larger than in the cohort as a whole (Figures II through V in the online-only Data Supplement), suggesting that our observations in the full cohort potentially underestimate the size of the actual difference between procedures.
Twelve-Month Data
Although our a priori primary aim was to compare the change in global CEC between RYGB and SG at 6 months postoperatively, all subjects were invited to return for 12-month follow-up testing. However, 4 subjects became pregnant, 2 started exclusionary medications, and 6 subjects did not present for 12-month visits. Thus, 55 subjects (SG, n=32; RYGB, n=23) attended 1-year follow-up assessments. Relative to CEC at 6 months, both surgical procedures produced similar improvements at 12 months after surgery (Figure VI in the online-only Data Supplement). However, despite these similar late changes, SG produced overall superior improvement in CEC from preoperative levels. In contrast to SG, at 1 year after surgery, post-RYGB subjects persistently exhibited significantly impaired global and cAMP-inducible CEC relative to normal BMI subjects (Table 10 ).
Discussion
We report the largest and longest study of HDL function after bariatric surgery to date and the first to compare the 2 most commonly performed procedures. This study also equals the length for the longest prospective study of the effects of any type of intervention on CEC. 24, 28, 29 Notably, we found that RYGB and SG differ significantly in the provoked changes in CEC that occur after surgery. The changes in CEC and differences in response between procedures at 6 months after surgery seem to be largely, but incompletely, explained by changes in Apo A1 and circulating HDL particles, which differed significantly between procedures irrespective of weight loss. However, among all subjects, despite loss of nearly one third of their body weight, and exhibiting increased HDL-C by 1 year after surgery, only half experienced improved CEC, a measure independently associated with incident cardiovascular events. 4, 5 In the current study, in agreement with others, we found obese subjects to have reduced CEC 3, 11 and weaker associations of CEC with HDL parameters, than normal BMI subjects. 26 Obese subjects also exhibited significantly lower concentrations of large HDL particles. This is particularly relevant, given 1 hypothesis for why HDL exhibits varying ability to perform cholesterol efflux. HDL particles are heterogeneous, and the concentrations of certain specific subclasses, such as large HDL 2 and the smallest pre-β1 particles, are felt to be most important in regard to mediating CEC and CVD protection. 30, 31 Previously, a 6-month study of premenopausal women without the metabolic syndrome undergoing RYGB found impaired ABCA1-mediated CEC after RYGB, 25 in agreement with our findings in cAMP-inducible CEC. Subjects in that study exhibited increased HDL-C and large HDL 2 particles, as well as SR-BI (scavenger receptor class B type I)-mediated and ABCG1 (ATP-binding cassette transporter G1)-mediated CEC at 6 months after surgery. Postoperative HDL 2 particles, specifically, were found to have greater ability to mediate cholesterol efflux via SR-BI relative to preoperative HDL 2 .
In contrast, in our cohort of equal numbers of subjects with and without the metabolic syndrome before surgery, RYGB did not improve non-ABCA1-specific CEC. Further, changes in the concentration of large HDL particles were not associated with the observed changes in non-ABCA1-specific CEC after RYGB.
In our direct comparison of procedures, SG produced superior changes to measures of HDL function in CEC relative to RYGB. Recently, in a very small group of adolescent males who underwent SG, Davidson et al 24 observed a 12% increase in global CEC at 1 year (nearly identical to the improvement we observed in SG subjects). In their study, in which Apo A1 was not quantified, the authors suggested that an increase specifically in large HDL particles was responsible for the observed improvement in CEC. Similar to both of the above-cited studies, we found concentrations of large HDL particles increased substantially and similarly after both procedures. However, in contrast to the findings in those smaller studies, the change specifically of large HDL particles was not predictive of changes in CEC in our subjects. We did observe strong associations of CEC changes with changes in HDL-C, total HDL particles, and Apo A1, all particles which exhibited preferable changes after SG versus RYGB, and seem to partially explain the superiority of the former procedure on the outcome of CEC.
Although both achieve marked and rapid weight loss, RYGB and SG are very different surgical procedures. SG, a relatively new bariatric surgical technique, 32 has rapidly become the most commonly performed bariatric procedure in the United States. 33 However, the metabolic changes after this procedure, and the mechanisms driving these changes, remain poorly understood. RYGB involves creation of a small proximal gastric pouch that is anastomosed to the jejunum. The excluded, but retained, stomach and duodenum are anastomosed to the distal jejunum. SG consists of the removal of the gastric fundus and most of the gastric body, but no anastomoses. Given the considerable differences in gastrointestinal anatomy between procedures, it is perhaps not surprising that they produce differing effects on lipid metabolism, including HDL function. For example, the bypass of the duodenum and part of the jejunum, locations of Apo A1 synthesis, Apo A1 indicates apolipoprotein A1; CETP, cholesterol ester transfer protein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment-insulin resistance; hsCRP, high-sensitivity C-reactive protein; and LDL-C, low-density lipoprotein cholesterol.
in RYGB but not SG, may at least partly explain the contrasting response of the 2 procedures. Reductions in HDL-C observed with the use of a duodenal liner device lend support to this hypothesis. 34 Another potential mechanism, suggested by animal models, is the increased expression of PPARα (peroxisome proliferator-activated receptor alpha) after SG. 35 Increased PPARα signaling upregulates Apo A1 production 36 and may suppress Apo A1 turnover and increase CEC, 37 as we observed in subjects after SG. Finally, the anatomic rearrangement of RYGB is known to increase levels of circulating bile acids, 38 compounds which have been shown to reduce Apo A1 expression via their agonism of the farsenoid X receptor. 39 Our novel observations open up many interesting questions to pursue in future studies. Foremost are the reasons behind the differences in response by surgery and variation in response of apparently similar patients undergoing the same procedure. In addition, after SG, but not RYGB, we found strong correlations of changes in Apo A1 and small HDL particles with cAMP-inducible CEC. This observation suggests that some unmeasured characteristics of the particles, or other factors, that are differentially affected by the 2 procedures, may partially modulate HDL function in obesity. One possibility may be pre-β HDL, which was not measured in this study. It is delipidated Apo A1 and small HDL particles which mediate efflux through ABCA1, which our cAMP-inducible CEC measure attempts to represent. 40 Asztalos et al 41 observed increased HDL-C, but decreased pre-β 1 HDL at 12 months after RYGB, in 19 severely obese women. The effects of SG on this particle are unknown and could partially explain the different effects of procedures on cAMP-inducible CEC and lack of postoperative associations with HDL-related parameters with this specific measure after RYGB.
Additional prominent hypotheses for varied HDL functionality include variations within the protein cargo and the burden of post-translational inflammatory Apo A1 modifications on HDL particles, which have been demonstrated to influence CEC. 6, [42] [43] [44] We hypothesized that reducing the systemic inflammation associated with obesity 45 via bariatric surgery would lead to improved HDL function in CEC. However, despite marked and similar reductions in markers of systemic inflammation among both procedures, there were differential responses in CEC as discussed above. Further, levels of serum inflammatory markers did not associate with preoperative CEC or with postoperative changes in CEC. The absence of association of serum inflammatory markers with CEC was also noted in the Dallas Heart Study, 5 suggesting that these nonspecific blood measures may not represent the propensity for inflammatory modification of HDL particles or at least any associated dysfunction.
Limitations
Our study has many limitations. Assignment to undergo the particular surgical procedure performed was not random. However, the only difference in preoperative characteristics between the 2 groups was a slight, not clinically significant, difference in age. In addition, our study sample consisted of a relatively homogenous population that both reflected the predominant composition of our clinical population and served to reduce confounding in our small sample. As a result, we cannot necessarily extrapolate our findings to other groups, such as older patients, other races, and men.
Another limitation is that the method for assessing CEC does not involve an individual's macrophages, but cultured macrophages in vitro. This may be particularly relevant; as recently, expressions of ABCA1 and ABCG1 were reported to be decreased in the monocytes of obese individuals, 46 calling into question how representative of in vivo CEC our measure may be. Further, we assessed cholesterol efflux to apoBdepleted serum. These assays do not allow for determination of bidirectional efflux driven by whole serum or that mediated specifically by ABCG1 or SR-BI. Nonetheless, the assay used in this study has been inversely associated with prevalent and incident CVD in multiple, diverse populations.
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Conclusions
This is the largest and longest study of CEC after bariatric surgery to date and the only parallel prospective comparison of 2 procedures on this outcome. We observed contrasting changes in CEC at 6 months after SG and RYGB, with superior improvements in Apo A1, HDL-C, and our primary end point of CEC-a measure predictive of prospective cardiovascular events-after SG. Our study makes a major contribution to the knowledge surrounding the metabolic effects of different bariatric surgical techniques. The changes in CEC and differences between procedures seem to be largely statistically explained by altered concentrations of Apo A1 or HDL particles after surgery. The relevance is profound as there is great need to better understand the metabolic effects of the ≈200 000 bariatric surgeries performed annually in the United States, particularly as almost half of bariatric surgery patients are <40 years old, 47 and may face unknown or unappreciated outcomes of the procedures 48 for decades. In addition, further study of the mechanisms underlying these changes may lead to improved understanding of the factors governing CEC and potential therapeutic interventions to improve CEC and reduce CVD risk in obese and nonobese patients. 
